Patient handout

Hypertensive encephalopathy (HTN crisis with cerebral edema / AMS / papilledema)

PRODUCTION

1. Your condition

This handout is for hypertensive encephalopathy (htn crisis with cerebral edema / ams / papilledema). Your care team identified this based on: sbp >180 + ams / severe headache / papilledema / vision change without focal deficit (acc/aha 2025 htn; vaughan lancet 2000 pmid 10972386).

Other reasons your team may use this plan: funduscopy showing papilledema / hemorrhages / exudates (keith-wagner-barker grade iii/iv); mri showing posterior reversible encephalopathy syndrome (pres) / parieto-occipital edema pattern (vaughan lancet 2000 pmid 10972386).

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

Medication	Starting dose	How	When	What it does
nicardipine	5 mg/h IV, titrate by 2.5 mg/h q5-15 min, max 15 mg/h	IV	continuous	ACC/AHA 2025 first-line — predictable cerebral autoregulation effect; titratable; no CSF/ICP issues; preferred over labetalol given selective vasodilation
clevidipine	1-2 mg/h IV, titrate q90 sec	IV	continuous	Ultra-short half-life allows tight control + minute-to-minute titration; lipid emulsion (avoid egg/soy allergy)
labetalol	20 mg IV q10 min (max 300 mg cumulative) OR 0.5-2 mg/min infusion	IV	bolus or infusion	Mixed α/β useful when sympathetic drive is high; no reflex tachycardia (ACC/AHA 2025)
AVOID nitroprusside	AVOID	N/A	N/A	Cyanide toxicity (especially eGFR <30 + duration >24 h); thiocyanate accumulation → may worsen ICP via venodilation; ACC/AHA 2025 AVOID in encephalopathy
AVOID hydralazine	AVOID	N/A	N/A	Unpredictable BP drop magnitude + delayed onset → risk of overshoot through autoregulation floor; reserve for pregnancy phenotype
AVOID nimodipine	AVOID	N/A	N/A	Nimodipine is SAH-only indication (vasospasm prophylaxis per AHA SAH guidelines); not for general HTN encephalopathy

Plan: Hypertensive encephalopathy — autoregulation-aware IV titration; MAP ↓ ≤25% in 1 h; SBP <140-160 within 6 h

3. When to call your provider

Contact your care team if any of the following happen:

BP rebound → return to ED
New neuro symptom → urgent re-eval

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

GCS decline OR new focal deficit during titration — indicates BP drop has overshot through right-shifted cerebral autoregulation floor → ischemic conversion risk(life-threatening)
Hypertensive encephalopathy progressing to coma / GCS <8 / posturing despite BP titration(life-threatening)
New focal neuro deficit on serial exam during treatment — reclassifies syndrome from encephalopathy to ICH or ischemic stroke(life-threatening)
Recurrent or prolonged seizures during encephalopathy — status epilepticus + ongoing PRES(life-threatening)
KWB grade IV papilledema with progressive vision loss — risk of permanent visual deficit if BP not lowered

5. Follow-up

Transition to oral 4-tier ladder once stable × 6-12 h; 1-week neuro + cardiology + ophthalmology follow-up; MRI at 4-6 wk to confirm PRES resolution; secondary cause workup

6. Sources

Guideline: 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia, PMID 38613493) + AHA/ASA 2022 ICH (PMID 35138133) — disambiguation neighbor